These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 17728218

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 5. Prostate carcinoma detection and increased prostate-specific antigen levels after 4 years in Dutch and Japanese males who had no evidence of disease at initial screening.
    Ito K, Raaijmakers R, Roobol M, Wildhagen M, Yamanaka H, Schröder FH.
    Cancer; 2005 Jan 15; 103(2):242-50. PubMed ID: 15578715
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Roemeling S, Roobol MJ, Gosselaar C, Schröder FH.
    Prostate; 2006 Jul 01; 66(10):1076-81. PubMed ID: 16637077
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Extent of prostate-specific antigen contamination in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Luján M, Páez A, Pascual C, Angulo J, Miravalles E, Berenguer A.
    Eur Urol; 2006 Dec 01; 50(6):1234-40; discussion 1239-40. PubMed ID: 16704893
    [Abstract] [Full Text] [Related]

  • 11. 4-year prostate specific antigen progression and diagnosis of prostate cancer in the European Randomized Study of Screening for Prostate Cancer, section Rotterdam.
    Schröder FH, Raaijmakers R, Postma R, van der Kwast TH, Roobol MJ.
    J Urol; 2005 Aug 01; 174(2):489-94; discussion 493-4. PubMed ID: 16006878
    [Abstract] [Full Text] [Related]

  • 12. Tumor characteristics and prognostic factors in two subsequent screening rounds with four-year interval within prostate cancer screening trial, ERSPC Rotterdam.
    van der Cruijsen-Koeter IW, Roobol MJ, Wildhagen MF, van der Kwast TH, Kirkels WJ, Schröder FH.
    Urology; 2006 Sep 01; 68(3):615-20. PubMed ID: 17010732
    [Abstract] [Full Text] [Related]

  • 13. No reason for immediate repeat sextant biopsy after negative initial sextant biopsy in men with PSA level of 4.0 ng/mL or greater (ERSPC, Rotterdam).
    Roobol MJ, van der Cruijsen IW, Schröder FH.
    Urology; 2004 May 01; 63(5):892-7; discussion 897-9. PubMed ID: 15134973
    [Abstract] [Full Text] [Related]

  • 14. Cancer detection and cancer characteristics in the European Randomized Study of Screening for Prostate Cancer (ERSPC)--Section Rotterdam. A comparison of two rounds of screening.
    Postma R, Schröder FH, van Leenders GJ, Hoedemaeker RF, Vis AN, Roobol MJ, van der Kwast TH.
    Eur Urol; 2007 Jul 01; 52(1):89-97. PubMed ID: 17257742
    [Abstract] [Full Text] [Related]

  • 15. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X, van Leeuwen PJ, Bul M, Otto SJ, de Koning HJ, Bangma CH, Schröder FH, Roobol MJ.
    Eur Urol; 2011 Aug 01; 60(2):330-6. PubMed ID: 21601352
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Prostate cancer mortality in screen and clinically detected prostate cancer: estimating the screening benefit.
    van Leeuwen PJ, Connolly D, Gavin A, Roobol MJ, Black A, Bangma CH, Schröder FH.
    Eur J Cancer; 2010 Jan 01; 46(2):377-83. PubMed ID: 19804966
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 37.